Thermal ablation for asthma: current status and technique

Vol 9, Supplement 2 (March 2017)
Review Article

William Krmisky 1, Michal J. Sobieszczyk 2, Saiyad Sarkar 3

1Interventional Pulmonary and Critical Care Medicine, MedStar Franklin Square Hospital Center, Baltimore, Maryland, USA; 2Pulmonary and Critical Care Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA; 3Interventional Pulmonary and Critical Care Medicine, MedStar Franklin Square Hospital Center, Baltimore, Maryland, USA

Contributions: (I) Conception and design: W Krimsky; (II) Administrative support: MJ Sobieszczyk, S Sarkar; (III) Provision of study materials or patients: MJ Sobieszczyk; (IV) Collection and assembly of data: MJ Sobieszczyk; (V) Data analysis and interpretation: MJ Sobieszczyk; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: William Krimsky, MD. Interventional Pulmonary and Critical Care Medicine, MedStar Franklin Square Hospital Center, 9103 Franklin Square Drive Suite 300 Baltimore, MD 21237, USA. Email: This email address is being protected from spambots. You need JavaScript enabled to view it. .

Abstract: Bronchial thermoplasty (BT) is a novel technique used in the treatment of severe asthma. A catheter is advanced through the bronchoscope and directed radiofrequency waves are applied to the segmental bronchi to reduce airway smooth muscle mass. Several randomized clinical trials demonstrate improvement in quality of life and reduction in exacerbation rates after treatment. BT is a safe and cost effective treatment option for severe asthma which is refractory to medical treatment. Further studies are needed in order to better describe the mechanism of action and the asthma subphenotype that was best benefit from this treatment.

doi: 10.21037/jtd.2016.11.113

Article Options

Abstract
PDF
HTML

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: The Lancet on Twitter: "In 2015, #pollution was responsible for 3 ti… https://t.co/67ta0PuWEX, see more https://t.co/CpGiFuOOYd
44mreplyretweetfavorite
Interasma RT @euforea: Inauguration of the Euforea fund at LUF, paving the way for better research in airway diseases. @LeuvenU https://t.co/D8wOLuKz
6hreplyretweetfavorite
Interasma RT @Aller_MD: Tracing cell death pathway points to drug targets for brain damage, kidney injury, #asthma https://t.co/aUrjIceDa9
6hreplyretweetfavorite
6hreplyretweetfavorite
Interasma Interasma https://t.co/benOb7sQz7 - top stories by @FloodBreda
8hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma